key: cord-0898088-o53s50ez
authors: Li, Jing-Xin; Zhu, Feng-Cai
title: Adjuvantation helps to optimise COVID-19 vaccine candidate
date: 2021-03-08
journal: Lancet Infect Dis
DOI: 10.1016/s1473-3099(21)00094-3
sha: 8930e544f3036e333b07cce81678fa76231de594
doc_id: 898088
cord_uid: o53s50ez

nan

As of Feb 6, 2021, the global COVID19 pandemic, caused by SARS-CoV-2, has resulted in over 103 million confirmed cases and 2·22 million deaths worldwide, and the situation is getting worse. 1 To date, eleven COVID-19 vaccines have been approved for emergency use or conditional licensure by at least one country. However, the production and supply of these vaccines are still inadequate, as they will not be available to cover the global population within a short period of time. Developed countries have purchased approximately 70% of the authorised novel COVID-19 vaccines, which could skew the epidemics further toward low-income and middle-income countries and exacerbate overburdened public health-care resources. COVID-19 vaccines from multiple manufacturers will be needed to address the global need. BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine, formulated with a toll-like receptor (TLR) 7/8 agonist molecule (IMDG) adsorbed to alum (Algel), and manufactured and produced by Bharat Biotech (India). 2 In The Lancet Infectious Diseases, Raches Ella and colleagues 3 report on the safety and immunogenicity of BBV152 in a double-blind, randomised, multicentre, phase 2 trial, and describe the persistence of immune responses at 3 months follow-up from the double-blind, randomised, phase 1 trial. 2 The results showed that two intramuscular injections of 6 µg BBV152 with Algel-IMDG administered 4 weeks apart induced seroconversion (plaque-reduction neutralisation test [PRNT 50 ]) in 174 (98·3% [95% CI 95·1-99·6]) of 177 participants, and geometric mean titres (GMT; microneutralisation assay [MNT 50 ]) of neutralising antibodies of 160·1 (95% CI 135·8-188·8) on day 56 (4 weeks after the second dose). BBV152 was also found to induce a persistent immune response, with high neutralising antibody titres observed in phase 1 participants at 3 months after the In trials of two other alum-adjuvanted inactivated vaccines, the overall efficacy of BBIBP-CorV is approximately 79·3% and of CoronaVac is approximately 50·4%, and both vaccines reportedly provide 100% protection against severe COVID-19. 4,5 In the absence of standardised SARS-CoV-2 reference assays and established serological immunogenic correlates of protection, it is not possible to predict the potential efficacy of BBV152 according to the immunogenicity data. However, experience with other vaccines tells us that higher vaccine-induced neutralising antibody titres are more likely to result in better and longer protection than lower vaccine-induced neutralising antibody titres. Phase 1 and 2 participants who received the twodose 6 µg with Algel-IMDG showed similar neutralising antibody titres to a panel of convalescent SARS-CoV-2 serum samples from symptomatic COVID-19 patients, and neutralising antibody titres were higher in the 6 µg with Algel-IMDG group than the Algel-only control group in phase 1 trial participants. In addition, both 3 µg with Algel-IMDG and 6 µg with Algel-IMDG formulations elicited T-cell responses that were biased to T-helper-1 (Th1) cells at 2 weeks after the second dose (day 42), and serum samples from participants in the 6 µg with Algel-IMDG have been shown to neutralise a variant of concern (B.1.1.7 or 20B/501Y. V1). Therefore, we are expecting BBV152 to show significant efficacy against COVID-19 in the ongoing phase 3 trial (NCT04641481).

The inactivated whole-virus vaccine platform is the most well established manufacturing platform for vaccine production, and aluminium salts are the most commonly used adjuvants used in human vaccines. Thus, an alumadjuvanted whole-virion inactivated vaccine is a logical step in the development of a COVID-19 vaccine. However, alum-adjuvanted vaccines have obvious limitations, such as requiring multiple doses for induced protection, and driving a Th2-polarised response over a Th1-polarised response. 6 The BBV152 vaccine, adjuvanted with alum and a TLR 7/8 agonist, is designed to enhance both humoral and Th1-skewed cellular immune responses after immunisation by optimising the inactivated vaccine formulation.

In the phase 2 trial, Ella and colleagues 3 reported that the 6 μg with Algel-IMDG formulation had low reactogenicity and a good safety profile, similar to the previously reported CoronaVac and BBIBP-CorV vaccines. 7, 8 All adverse events were mild or moderate in severity, and no serious adverse reactions were reported. However, we do not have complete safety data for BBV152 yet because of the small number of participants and the short observation period in these studies. 2,3 Rare adverse reactions associated with vaccination, such as acute anaphylaxis or autoimmune diseases, are unlikely to be observed in clinical trials. Therefore, a good pharmacovigilance system for BBV152 needs to be established, especially considering that Algel-IMDG is a new adjuvant and it is the first time that an Algel-IMDG adjuvanted vaccine has been approved for use in a large population. Therefore, identifying potential safety signals will be very important.

Overall, Algel-IMDG-adjuvanted BBV152 was safe, immunogenic, and able to induce Th1-biased T-cell responses, and could therefore be a potentially superior vaccine over the alum-adjuvanted inactivated COVID-19 vaccines.

We declare no competing interests. 

The economic costs of the pandemic have been high, and vaccines offer an exit strategy. In The Lancet Infectious Diseases, Frank Sandmann and colleagues model a range of future scenarios in the UK depending on vaccine efficacy, duration of protection, and use of physical distancing, and the respective health and economic impacts of these scenarios. 1 This study is the first full economic evaluation of different vaccination scenarios compared with an unmitigated epidemic, with varying degrees of physical distancing. It shows that lockdowns and physical distancing reduce economic losses, which refutes the false perceived dichotomy of protecting the economy at the expense of pandemic control. The authors also show the health and economic benefits of mass vaccination of adults in the UK.

In the best-case vaccination scenario, with 95% vaccine efficacy and 3-year protection against infection, requirements for increased physical distancing (ie, reducing contacts by 90% outside of the home) are minimal. In the worst-case scenario, with 50% vaccine efficacy and 45-week protection against disease, but not infection, recurrent epidemics will occur with ongoing need for increased physical distancing. 1 Although the study considers hypothetical scenarios of higher and lower vaccine efficacy, there is already wide variation in efficacy of available vaccines. Phase 3 trials show 63-95% efficacy against symptomatic infection, with the highest efficacy shown for mRNA vaccines. 2-4 The ChAdOx1 nCoV-19 vaccine trial is the only one to date presenting data on prevention of asymptomatic infection, and efficacy is much lower for this endpoint. 2 Economic losses are substantially less when highefficacy vaccines are used, whereas lower-efficacy vaccines with short duration of protection will provide marginal benefits compared with no vaccination. 1 The best-case vaccination scenario will result in substantial economic gains compared with no vaccination, but the worst-case scenario might not, depending on vaccine costs and the wider societal cost of ongoing lockdowns. Duration of vaccine-induced immunity is also an important factor that affects the economic value of vaccination, but vaccine-induced protection could be extended by boosters. Therefore, the most influential factor is the efficacy of the vaccines being used, and thus vaccine choices matter enormously for economic recovery. Governments should grasp the importance of procuring the highest-efficacy vaccines as the route to achieving a best-case economic scenario. In countries that rely on lower-efficacy vaccines, be it by choice or lack thereof, the long-term health and economic burden might be similar to if no vaccine were used, if a very high threshold (eg, 100 cases per 100 000 population) were used to trigger physical distancing measures.

The study shows that if natural immunity is long lasting, the economic value of immunisation decreases. 1 However, the mRNA vaccines result in higher neutralising antibody titres than in convalescent sera. 5 Furthermore, in Manaus, Brazil, where 76% of the population had been infected by October, 2020-higher than the hypothesised herd immunity threshold-a large second wave has since occurred. 6 In addition, variants of concern show evidence of vaccine escape. 7 The South African Government paused the planned rollout of the ChAdOx1 nCoV-19 vaccine because the efficacy against the B1.351 variant was found to be 10·4%. 8 All vaccines can be matched to emergent variants, but we are likely to face a situation of regular revision of vaccine antigens, which will add to future cost.

The variants of concern also pose a challenge because they are more contagious. If they become dominant, this will require higher vaccine coverage and higherefficacy vaccines, making a compelling case for use of the highest-efficacy vaccines at the outset to avoid

Recent advances in the discovery and delivery of TLR7/8 agonists as vaccine adjuvants

Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial